September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
AAV-mediated MMP3 expression from corneal endothelium as a targeted gene therapy approach for glaucoma
Author Affiliations & Notes
  • Jeffrey O'Callaghan
    Smurfit Institute of Genetics, Dublin, Ireland
  • Darragh Crosbie
    Smurfit Institute of Genetics, Dublin, Ireland
  • Paul Cassidy
    Smurfit Institute of Genetics, Dublin, Ireland
  • Marian M Humphries
    Smurfit Institute of Genetics, Dublin, Ireland
  • Anna-Sophia Kiang
    Smurfit Institute of Genetics, Dublin, Ireland
  • Joseph M. Sherwood
    Imperial College London, London, United Kingdom
  • Darryl R. Overby
    Imperial College London, London, United Kingdom
  • W Daniel Stamer
    Duke University, Durhim, North Carolina, United States
  • Lawrence Tam
    Smurfit Institute of Genetics, Dublin, Ireland
  • Peter Humphries
    Smurfit Institute of Genetics, Dublin, Ireland
  • Footnotes
    Commercial Relationships   Jeffrey O'Callaghan, None; Darragh Crosbie, None; Paul Cassidy, None; Marian Humphries, None; Anna-Sophia Kiang, None; Joseph Sherwood, None; Darryl Overby, None; W Stamer, None; Lawrence Tam, None; Peter Humphries, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 793. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jeffrey O'Callaghan, Darragh Crosbie, Paul Cassidy, Marian M Humphries, Anna-Sophia Kiang, Joseph M. Sherwood, Darryl R. Overby, W Daniel Stamer, Lawrence Tam, Peter Humphries; AAV-mediated MMP3 expression from corneal endothelium as a targeted gene therapy approach for glaucoma. Invest. Ophthalmol. Vis. Sci. 2016;57(12):793.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Matrix metalloproteinases (MMP) play an important role in remodeling of the extracellular matrix (ECM) within the drainage channels of the eye to control outflow resistance and thus IOP. This study assesses the therapeutic potential of increasing outflow facility via inoculation of an AAV virus expressing MMP3 in the corneal endothelium.

Methods : Transendothelial electrical resistance (TEER) and FITC-dextran assays were carried out to evaluate the effect of recombinant MMP-3 on the paracellular permeability of Schlemm’s canal endothelial (SCE) monolayers. Wildtype murine eyes (C57/BL6J) were intracamerally injected with an AAV2/9 vector (1x1011 AAV particles per eye) expressing a murine MMP3 cDNA driven by a CMV promoter, with contralateral AAV-2/9 expressing the CMV promoter with no transgene as controls. After 4 weeks, mouse eyes were enucleated and outflow facility was measured using the i-Perfusion system.

Results : Treatment of SCE cells with recombinant MMP-3 significantly increased paracellular permeability to 70kDa dextran 114-fold (p=0.0005) and reduced TEER values by 23% (p=0.015). Histological analysis of anterior segment flat mounts of C57/BL6J mice showed that intracameral inoculation of AAV2/9 specifically transduced the corneal endothelium, indicating the use of this serotype as a means to deliver MMP-3 to the conventional outflow pathway by following the natural flow of aqueous humour in the anterior chamber. We observed that intracameral delivery of an AAV2/9 vector expressing MMP3 from the corneal endothelium significantly increased outflow facility, on average, by 39% (p=0.008, N=7), as compared to contralateral controls.

Conclusions : The use of AAV vectors in directing expression of potentially therapeutic genes to the anterior chamber of the eye has not been explored for gene therapy as extensively as other ocular regions such as the retina. The secretory nature of MMPs renders the corneal endothelium a favourable site for protein expression, since the flow of aqueous humor will direct the secreted protein into the trabecular meshwork. In the current study, outflow facility was significantly increased, suggesting a realistic rationale for gene-based therapy.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×